...
首页> 外文期刊>Journal of Surgical Oncology >Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy.
【24h】

Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy.

机译:乳腺癌患者哨兵节点活检的安全性,在淋巴压术中的可视化失败后接受第二个放射性同位素注射的患者。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND AND OBJECTIVES: A failure to visualize axillary sentinel nodes in lymphoscintigraphy may lead to an unsuccessful sentinel node biopsy (SNB) and subsequent axillary lymph node dissection (ALND). To avoid unnecessary ALND, a second radioisotope injection may be given but has been considered hazardous. We investigated the axillary recurrence rate after tumor-negative SNB in breast cancer patients who received a second tracer injection after axillary visualization failure in lymphoscintigraphy. METHODS: Altogether 1,309 breast cancer patients who underwent a tumor-negative SNB without an ALND were included. Two hundred seven (15.8%) patients received a second tracer injection due to visualization failure in lymphoscintigraphy and 1,102 (84.2%) did not. All patients received a blue dye injection prior to the SNB. The median follow-up time was 43 months. RESULTS: No isolated cancer recurrences were diagnosed in the ipsilateral axilla among patients who received two radioisotope injections. Disease-free survival and overall survival were similar among patients with one or two radioisotope injections (P = 0.122 and P = 0.200, respectively). CONCLUSIONS: Additional radiocolloid tracer injection after axillary non-visualization in lymphoscintigraphy is safe and does not increase axillary recurrence risk after tumor-negative SNB. The results suggest that such patients can be safely managed with SNB without a need to perform an ALND.
机译:背景和目标:未能可视化淋巴管状症中的腋窝哨碱节点可能导致不成功的哨兵节点活组织检查(SNB)和随后的腋窝淋巴结解剖(ALND)。为了避免不必要的alnd,可以给出第二个放射性同位素注射,但已被认为是危险的。我们在乳腺癌患者肿瘤阴性SNB患者中调查了腋窝阴性SENB,在淋巴主张中腋窝可视化失败后接受第二个示踪剂注射。方法:制定了1,309名乳腺癌患者,在没有ALND的情况下接受肿瘤阴性SNB的患者。 20七(15.8%)患者因淋巴管状症的可视化失败而接受第二个示踪剂注射,1,102(84.2%)没有。所有患者在SNB之前均接受蓝色染料注射。中位后续时间为43个月。结果:未在接受两个放射性同位素注射的患者中诊断出在Ipsilatalal Axilla中诊断出分离的癌症复发。在一个或两个放射性同位素注射的患者中,无病的存活和整体存活率(p = 0.122和p = 0.200)。结论:淋巴管状后腋窝非可视化后额外的radiocolloid示踪剂注射是安全的,在肿瘤阴性SNB后不会增加腋生复发风险。结果表明,这些患者可以用SNB安全地管理,无需执行ALND。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号